Global dengue treatment market is expected to reach USD 2,121.43 million by 2031, from USD 878.54 million in 2023 growing at the CAGR of 11.6% in the forecast period of 2024 to 2031.
Market Segmentation:
Global Dengue Treatment Market, By Strains (DENV-2, DENV-3, DENV-1, DENV-4, and Others), Type (Vaccines and Acetaminophen), Severity (Mild to Moderate Dengue and Severe Dengue), Route of Administration (Parenteral and Oral), Mode of Purchase (Prescription and Over-the-Counter (OTC)), Gender (Male and Female), Age (Adult, Pediatric, and Geriatric), End User (Hospital, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies), By Countries (U.S., Canada, Mexico, Germany, U.K., Italy, France, Spain, Russia, Switzerland, Turkey, Belgium, Netherlands, Rest of Europe, Japan, China, South Korea, India, Singapore, Thailand, Indonesia, Malaysia, Philippines, Australia, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Egypt, Saudi Arabia, U.A.E., Israel, and Rest of Middle East and Africa) - Industry Trends and Forecast to 2031
Overview of Global Dengue treatment Market Dynamics:
- Driver
- Rising dengue incidence rate result in the demand for effective treatment
- Restrain
- Delay in the approval process of vaccines
- Opportunity
- Growing number of pipeline vaccines for dengue treatment
Market Players:
The key market players operating in the global dengue treatment market are listed below:
- Sanofi
- Takeda Pharmaceutical Company Limited
- Viatris Inc.
- Johnson & Johnson
- GSK plc.
- Perrigo Company PLC
- Baxter
- Fresenius Kabi USA
- Pfizer
- Hikma Pharmaceuticals PLC
- Sun Pharmaceutical Industries Ltd
- Teva Pharmaceuticals USA, Inc.
- Aurobindo Pharma
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 OBJECTIVES OF THE STUDY
- 1.2 MARKET DEFINITION
- 1.3 OVERVIEW OF THE GLOBAL DENGUE TREATMENT MARKET
- 1.4 CURRENCY AND PRICING
- 1.5 LIMITATIONS
- 1.6 MARKETS COVERED
2 MARKET SEGMENTATION
- 2.1 MARKETS COVERED
- 2.2 GEOGRAPHICAL SCOPE
- 2.3 YEARS CONSIDERED FOR THE STUDY
- 2.4 DBMR TRIPOD DATA VALIDATION MODEL
- 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
- 2.6 MULTIVARIATE MODELLING
- 2.7 MARKET APPLICATION COVERAGE GRID
- 2.8 PRODUCT LIFELINE CURVE
- 2.9 DBMR MARKET POSITION GRID
- 2.10 VENDOR SHARE ANALYSIS
- 2.11 SECONDARY SOURCES
- 2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
- 4.1 PESTEL ANALYSIS
- 4.2 PORTER'S FIVE FORCES
5 GLOBAL DENGUE TREATMENT MARKET: REGULATIONS
- 5.1 U.S. REGULATORY SCENARIO FOR DENGUE TREATMENT
- 5.2 EUROPE REGULATORY SCENARIO FOR DENGUE TREATMENT
- 5.3 DEVELOPING COUNTRIES REGULATORY FRAMEWORK
- 5.4 LEGISLATION FOR CONTROL OF DENGUE IN SINGAPORE
- 5.5 DVCRN DEVELOPING VACCINE REGULATORS NETWORK
6 MARKET OVERVIEW
- 6.1 DRIVERS
- 6.1.1 RISING DENGUE INCIDENCE RATE RESULT IN THE DEMAND FOR EFFECTIVE TREATMENT
- 6.1.2 RISING WAVE OF DENGUE VACCINE LAUNCHES
- 6.1.3 GOVERNMENT INITIATIVES AND VACCINATION PROGRAMS
- 6.1.4 GROWTH OF MEDICAL INSURANCE IN EMERGING COUNTRIES
- 6.2 RESTRAINTS
- 6.2.1 DELAY IN THE APPROVAL PROCESS OF VACCINES
- 6.2.2 LACK OF AWARENESS AND HEALTHCARE INFRASTRUCTURE FOR TREATMENT OF DENGUE
- 6.2.3 DIFFICULTY IN THE DETECTION ASSAY FOR DENGUE
- 6.3 OPPORTUNITIES
- 6.3.1 STRATEGIC COLLABORATION WITHIN THE PHARMACEUTICAL INDUSTRY FUELS THE MARKET
- 6.3.2 GROWING NUMBER OF PIPELINE VACCINES FOR DENGUE TREATMENT
- 6.3.3 RISING R&D INVESTMENT AND ACTIVITIES
- 6.4 CHALLENGES
- 6.4.1 HEALTHCARE SERVICES ARE LIMITEDLY ACCESSIBLE IN RURAL AREAS
- 6.4.2 HIGH COSTS OF TREATMENT RESTRICT THE FEASIBILITY OF COST-EFFECTIVE SOLUTIONS
7 GLOBAL DENGUE TREATMENT MARKET, BY STRAINS
- 7.1 OVERVIEW
- 7.2 DENV-2
- 7.3 DENV-3
- 7.4 DENV-1
- 7.5 DENV-4
- 7.6 OTHERS
8 GLOBAL DENGUE TREATMENT MARKET, BY TYPE
- 8.1 OVERVIEW
- 8.2 VACCINES
- 8.2.1 DENGVAXIA (CYD-TDV)
- 8.2.2 QDENGA
- 8.3 ACETAMINOPHEN
- 8.3.1 PARENTERAL
- 8.3.2 ORAL
- 8.3.3 OTHER
9 GLOBAL DENGUE TREATMENT MARKET, BY SEVERITY
- 9.1 OVERVIEW
- 9.2 MILD TO MODERATE DENGUE
- 9.3 SEVERE DENGUE
10 GLOBAL DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
- 10.1 OVERVIEW
- 10.2 PARENTERAL
- 10.2.1 SUB-CUTANEOUS
- 10.2.2 INTRAVENOUS
- 10.3 ORAL
- 10.3.1 TABLET
- 10.3.2 CAPSULES
- 10.3.3 OTHERS
11 GLOBAL DENGUE TREATMENT MARKET, BY MODE OF PURCHASE
- 11.1 OVERVIEW
- 11.2 PRESCRIPTION
- 11.3 OVER-THE-COUNTER (OTC)
12 GLOBAL DENGUE TREATMENT MARKET, BY GENDER
- 12.1 OVERVIEW
- 12.2 MALE
- 12.3 FEMALE
13 GLOBAL DENGUE TREATMENT MARKET, BY AGE
- 13.1 OVERVIEW
- 13.2 ADULT
- 13.3 PEDIATRIC
- 13.4 GERIATRIC
14 GLOBAL DENGUE TREATMENT MARKET, BY END USER
- 14.1 OVERVIEW
- 14.2 HOSPITAL
- 14.3 SPECIALTY CLINICS
- 14.4 HOME HEALTHCARE
- 14.5 OTHERS
15 GLOBAL DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL
- 15.1 OVERVIEW
- 15.2 RETAIL PHARMACIES
- 15.3 HOSPITAL PHARMACIES
- 15.4 ONLINE PHARMACIES
16 GLOBAL DENGUE TREATMENT MARKET, BY REGION
- 16.1 OVERVIEW
- 16.2 ASIA-PACIFIC
- 16.2.1 INDIA
- 16.2.2 CHINA
- 16.2.3 JAPAN
- 16.2.4 INDONESIA
- 16.2.5 MALAYSIA
- 16.2.6 THAILAND
- 16.2.7 AUSTRALIA
- 16.2.8 SOUTH KOREA
- 16.2.9 SINGAPORE
- 16.2.10 PHILIPPINES
- 16.2.11 REST OF ASIA-PACIFIC
- 16.3 SOUTH AMERICA
- 16.3.1 BRAZIL
- 16.3.2 ARGENTINA
- 16.3.3 REST OF SOUTH AMERICA
- 16.4 NORTH AMERICA
- 16.4.1 MEXICO
- 16.4.2 U.S.
- 16.4.3 CANADA
- 16.5 EUROPE
- 16.5.1 FRANCE
- 16.5.2 GERMANY
- 16.5.3 SPAIN
- 16.5.4 U.K.
- 16.5.5 BELGIUM
- 16.5.6 ITALY
- 16.5.7 NETHERLANDS
- 16.5.8 RUSSIA
- 16.5.9 SWITZERLAND
- 16.5.10 TURKEY
- 16.5.11 REST OF EUROPE
- 16.6 MIDDLE EAST AND AFRICA
- 16.6.1 EGYPT
- 16.6.2 SAUDI ARABIA
- 16.6.3 SOUTH AFRICA
- 16.6.4 U.A.E
- 16.6.5 ISRAEL
- 16.6.6 REST OF MIDDLE EAST AND AFRICA
17 GLOBAL DENGUE TREATMENT MARKET: COMPANY LANDSCAPE
- 17.1 COMPANY SHARE ANALYSIS: GLOBAL
- 17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
- 17.3 COMPANY SHARE ANALYSIS: EUROPE
- 17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
- 17.5 COMPANY SHARE ANALYSIS: SOUTH AMERICA
18 SWOT ANALYSIS
19 COMPANY PROFILE
- 19.1 SANOFI
- 19.1.1 COMPANY SNAPSHOT
- 19.1.2 REVENUE ANALYSIS
- 19.1.3 COMPANY SHARE ANALYSIS
- 19.1.4 PRODUCT PORTFOLIO
- 19.1.5 RECENT DEVELOPMENTS
- 19.2 TAKEDA PHARMACEUTICAL COMPANY LIMITED
- 19.2.1 COMPANY SNAPSHOT
- 19.2.2 REVENUE ANALYSIS
- 19.2.3 COMPANY SHARE ANALYSIS
- 19.2.4 PRODUCT PORTFOLIO
- 19.2.5 RECENT DEVELOPMENTS
- 19.3 VIATRIS INC.
- 19.3.1 COMPANY SNAPSHOT
- 19.3.2 REVENUE ANALYSIS
- 19.3.3 COMPANY SHARE ANALYSIS
- 19.3.4 PRODUCT PORTFOLIO
- 19.3.5 RECENT DEVELOPMENTS
- 19.4 JOHNSON & JOHNSON SERVICES, INC.
- 19.4.1 COMPANY SNAPSHOT
- 19.4.2 REVENUE ANALYSIS
- 19.4.3 COMPANY SHARE ANALYSIS
- 19.4.4 PRODUCT PORTFOLIO
- 19.4.5 RECENT DEVELOPMENT
- 19.5 GSK PLC.
- 19.5.1 COMPANY SNAPSHOT
- 19.5.2 REVENUE ANALYSIS
- 19.5.3 COMPANY SHARE ANALYSIS
- 19.5.4 PRODUCT PORTFOLIO
- 19.5.5 RECENT DEVELOPMENTS
- 19.6 AUROBINDO PHARMA
- 19.6.1 COMPANY SNAPSHOT
- 19.6.2 REVENUE ANALYSIS
- 19.6.3 PRODUCT PORTFOLIO
- 19.7 BAXTER
- 19.7.1 COMPANY SNAPSHOT
- 19.7.2 REVENUE ANALYSIS
- 19.7.3 PRODUCT PORTFOLIO
- 19.8 FRESENIUS KABI USA
- 19.8.1 COMPANY SNAPSHOT
- 19.8.2 PRODUCT PORTFOLIO
- 19.8.3 RECENT DEVELOPMENTS
- 19.9 HIKMA PHARMACEUTICALS
- 19.9.1 COMPANY SNAPSHOT
- 19.9.2 REVENUE ANALYSIS
- 19.9.3 PRODUCT PORTFOLIO
- 19.9.4 RECENT DEVELOPMENT
- 19.10 PERRIGO COMPANY PLC
- 19.10.1 COMPANY SNAPSHOT
- 19.10.2 REVENUE ANALYSIS
- 19.10.3 PRODUCT PORTFOLIO
- 19.10.4 RECENT DEVELOPMENT
- 19.11 PFIZER INC.
- 19.11.1 COMPANY SNAPSHOT
- 19.11.2 REVENUE ANALYSIS
- 19.11.3 PRODUCT PORTFOLIO
- 19.11.4 RECENT DEVELOPMENTS
- 19.12 SUN PHARMACEUTICAL INDUSTRIES LTD
- 19.12.1 COMPANY SNAPSHOT
- 19.12.2 REVENUE ANALYSIS
- 19.12.3 PRODUCT PORTFOLIO
- 19.12.4 RECENT DEVELOPMENT
- 19.13 TEVA PHARMACEUTICALS USA, INC.
- 19.13.1 COMPANY SNAPSHOT
- 19.13.2 REVENUE ANALYSIS
- 19.13.3 PRODUCT PORTFOLIO
- 19.13.4 RECENT DEVELOPMENT
20 QUESTIONNAIRE
21 RELATED REPORTS